SPRY
HealthcareARS Pharmaceuticals, Inc. · Biotechnology · $790M
What is ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals is a small-cap biopharmaceutical company focused on a needle-free alternative to epinephrine auto-injectors for people at risk of severe allergic reactions. Headquartered in San Diego, California, the company is built around a single novel product platform.
The company develops and commercializes Neffy, an intranasal epinephrine nasal spray designed for rapid absorption without a needle. Neffy targets patients — and their caregivers — who face life-threatening allergic reactions to foods, medications, or insect stings. Rather than competing on a crowded drug class, ARS Pharmaceuticals is pursuing a delivery-method differentiation strategy, aiming to replace the traditional epinephrine auto-injector with a more accessible nasal spray format.
ARS Pharmaceuticals was incorporated in 2020 and is based in San Diego, California.
- Neffy — low-dose intranasal epinephrine nasal spray for anaphylaxis
- ARS-1 absorption technology platform for intranasal drug delivery
- Patient and caregiver-focused severe allergic reaction treatment
Is SPRY a Good Stock to Buy?
UQS Score rates SPRY as Poor overall, reflecting meaningful structural challenges across several key pillars.
The most constructive element in SPRY's profile is its Risk pillar, which rates Good — suggesting the company carries a relatively manageable risk profile compared to many early-stage peers in the sector. The Growth pillar comes in at Neutral, indicating that while the commercial trajectory for Neffy is not yet compelling, it is not entirely absent either.
Both the Quality and Moat pillars rate Weak, pointing to limited financial durability and a narrow competitive position. Valuation is Elevated, meaning the market may already be pricing in an optimistic scenario for a company still in early commercialization.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SPRY pay dividends?
No — ARS Pharmaceuticals, Inc. does not currently pay a dividend.
SPRY does not pay a dividend. For an early-stage biopharmaceutical company like ARS Pharmaceuticals, this is expected — available capital is directed toward clinical development, regulatory work, and the commercialization of Neffy rather than shareholder distributions. Income-focused investors should look elsewhere in the healthcare sector.
When does SPRY report earnings?
ARS Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
As an early-stage commercial company, quarterly results for SPRY tend to center on Neffy adoption trends, operating expense management, and cash runway updates rather than traditional profitability metrics. Revenue visibility remains limited given the product's recent market entry.
For the most recent quarter's results, see ARS Pharmaceuticals' investor relations page.
SPRY Price History
-71.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ARS Pharmaceuticals, Inc.?
Based on ARS Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SPRY Long-term Outlook
The fundamental outlook for SPRY hinges almost entirely on Neffy's commercial uptake in the epinephrine market. The Growth pillar's Neutral rating suggests the path forward is uncertain but not without potential. However, the Weak Quality and Moat ratings indicate the company lacks the financial foundation and competitive insulation to absorb setbacks easily. An Elevated Valuation adds further caution — the current price appears to embed expectations that may be difficult to meet in the near term.
Growth drivers
- Expanding physician and patient adoption of needle-free epinephrine delivery
- Potential label expansions or additional indications for the ARS-1 platform
- Growing awareness of anaphylaxis preparedness driving demand for accessible formats
Key risks
- Weak Quality pillar signals limited financial durability if commercialization stalls
- Elevated Valuation leaves little margin of safety if growth disappoints
- Narrow single-product focus creates concentration risk in a competitive allergy treatment market
SPRY vs Peers
ARS Pharmaceuticals operates in a niche corner of the specialty pharma space, but it shares the small-cap biotech landscape with other development-stage companies.
Design Therapeutics focuses on genetic disease through small-molecule platform technology, targeting a different therapeutic area than ARS Pharmaceuticals' allergy-focused delivery innovation.
MeiraGTx pursues gene therapy across multiple disease areas, representing a higher-complexity, higher-investment development model compared to SPRY's single-product nasal spray approach.
CytomX develops conditionally activated antibody therapies for oncology, placing it in a distinct therapeutic category with a different risk and commercial profile than ARS Pharmaceuticals.
Frequently Asked Questions
What does ARS Pharmaceuticals do?
ARS Pharmaceuticals develops Neffy, an intranasal epinephrine nasal spray for people at risk of severe allergic reactions. The product is designed as a needle-free alternative to traditional epinephrine auto-injectors, targeting patients and caregivers managing anaphylaxis risk from food, medications, or insect stings.
Does SPRY pay dividends?
No, SPRY does not currently pay a dividend. As an early-stage commercial biopharmaceutical company, ARS Pharmaceuticals directs its resources toward product commercialization and platform development rather than shareholder distributions. Dividend payments are not typical for companies at this stage.
When does SPRY report earnings?
ARS Pharmaceuticals reports on a quarterly cadence, consistent with US-listed public companies. Specific upcoming dates are not covered by our data source — check the company's investor relations page for the current earnings calendar.
Is SPRY a good stock to buy?
The UQS Score rates SPRY as Poor overall. The Risk pillar is the strongest element, while Quality, Moat, and Valuation present meaningful concerns. Whether SPRY fits a portfolio depends on individual risk tolerance and investment thesis. The complete pillar breakdown is available to UQS Pro members.
Is SPRY overvalued?
SPRY's Valuation pillar is rated Elevated under the UQS framework, suggesting the current market price may reflect optimistic assumptions about Neffy's commercial trajectory. For an early-stage company with Weak Quality and Moat ratings, an elevated valuation leaves limited margin of safety.
How does SPRY compare to its competitors?
SPRY operates in a different therapeutic niche than peers like Design Therapeutics, MeiraGTx, and CytomX Therapeutics. While all are small-cap development-stage biotechs, ARS Pharmaceuticals is uniquely focused on drug delivery innovation for anaphylaxis rather than gene therapy or oncology platforms.
What is SPRY's market cap bracket?
SPRY is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility, limited analyst coverage, and greater sensitivity to clinical or commercial milestones compared to large- or mega-cap healthcare companies.
Who founded ARS Pharmaceuticals?
ARS Pharmaceuticals was incorporated in 2020. Founding details are publicly available through the company's official disclosures and SEC filings, which provide the most accurate and current information on its leadership history.
Is SPRY a long-term quality investment?
As a long-term quality indicator, the UQS Score rates SPRY as Poor. The Weak Quality and Moat pillars suggest the company has not yet built the financial durability or competitive positioning typically associated with long-term compounders. Neffy's commercial success would need to materially improve these fundamentals over time.
What is the main competitive advantage of ARS Pharmaceuticals?
ARS Pharmaceuticals' differentiation rests on its intranasal delivery technology — offering a needle-free format for epinephrine that could improve accessibility and compliance for anaphylaxis patients. However, the UQS Moat pillar rates this advantage as Weak, indicating the competitive position is not yet well-established.
What sector does SPRY belong to?
SPRY belongs to the Healthcare sector, specifically within specialty biopharmaceuticals. The company sits at the intersection of drug delivery innovation and allergy treatment, targeting a niche but potentially significant market for anaphylaxis management.
Is SPRY a growth stock or value stock?
Based on UQS pillar labels, SPRY shows a Neutral Growth profile and an Elevated Valuation — a combination that fits neither a classic growth stock nor a value stock profile. It is better characterized as an early-stage commercial bet on a single product's market adoption.
Unlock Full SPRY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare SPRY against sector peers side by side
- ✓See the full risk and valuation breakdown in detail
- ✓Get the complete analyst-style quality report for SPRY
Pro Analysis
SPRY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 30.2 | 7.9 | 21.0 | 59.0 | 74.7 | 0.0 | — |
SPRY — Pillar Breakdown
Quality
— 7.9/100 (25%)ARS Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 59.0/100 (20%)ARS Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 64.6/100 (15%)ARS Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ARS Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 21/100 (25%)ARS Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SPRY.
Score Composition
Financial Data
More Stock Analysis
How is the SPRY UQS Score Calculated?
The UQS (Unified Quality Score) for ARS Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ARS Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ARS Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.